메뉴 건너뛰기




Volumn 32, Issue 10, 2017, Pages 1365-1370

New perspectives on study designs for evaluating neuroprotection in Parkinson's disease

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; NEUROPROTECTIVE AGENT;

EID: 85031284580     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.27055     Document Type: Article
Times cited : (11)

References (29)
  • 1
    • 23844434211 scopus 로고    scopus 로고
    • The non-motor symptom complex of Parkinson's disease: A comprehensive assessment is essential
    • Chaudhuri KR, Yates L, Martinez-Martin P. The non-motor symptom complex of Parkinson's disease: A comprehensive assessment is essential. Curr Neurol Neurosci Rep 2005;5:275-283.
    • (2005) Curr Neurol Neurosci Rep , vol.5 , pp. 275-283
    • Chaudhuri, K.R.1    Yates, L.2    Martinez-Martin, P.3
  • 2
    • 33645755812 scopus 로고    scopus 로고
    • The Parkinson's complex: parkinsonism is just the tip of the iceberg
    • Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006;59:591-596.
    • (2006) Ann Neurol , vol.59 , pp. 591-596
    • Langston, J.W.1
  • 3
    • 79551477291 scopus 로고    scopus 로고
    • Multi-organ autonomic dysfunction in Parkinson disease
    • Jain S. Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism Relat Disord 2011;17:77-83.
    • (2011) Parkinsonism Relat Disord , vol.17 , pp. 77-83
    • Jain, S.1
  • 4
    • 0141741347 scopus 로고    scopus 로고
    • Parkinson's disease: Mechanisms and models
    • Dauer W, Przedborski S. Parkinson's disease: Mechanisms and models. Neuron. 2003;39:889-909.
    • (2003) Neuron. , vol.39 , pp. 889-909
    • Dauer, W.1    Przedborski, S.2
  • 5
    • 0141741347 scopus 로고    scopus 로고
    • Parkinson's disease: mechanisms and models
    • Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
    • (2003) Neuron , vol.39 , pp. 889-909
    • Dauer, W.1    Przedborski, S.2
  • 6
    • 0032890731 scopus 로고    scopus 로고
    • Parkinson disease, the effect of levodopa, and the ELLDOPA trial
    • Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol 1999;56:529-535.
    • (1999) Arch Neurol , vol.56 , pp. 529-535
    • Fahn, S.1
  • 7
    • 58349122472 scopus 로고    scopus 로고
    • Why have we failed to achieve neuroprotection in Parkinson's disease?
    • Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol 2008;64(suppl 2):S101-S110.
    • (2008) Ann Neurol , vol.64 , pp. S101-S110
    • Olanow, C.W.1    Kieburtz, K.2    Schapira, A.H.3
  • 8
    • 84873478145 scopus 로고    scopus 로고
    • Trial designs used to study neuroprotective therapy in Parkinson's disease
    • Lang AE, Melamed E, Poewe W, Rascol O. Trial designs used to study neuroprotective therapy in Parkinson's disease. Mov Disord 2013;28:86-95.
    • (2013) Mov Disord , vol.28 , pp. 86-95
    • Lang, A.E.1    Melamed, E.2    Poewe, W.3    Rascol, O.4
  • 9
    • 84905455009 scopus 로고    scopus 로고
    • Network modulation following sham surgery in Parkinson's disease
    • Ko JH, Feigin A, Mattis PJ, et al. Network modulation following sham surgery in Parkinson's disease. J Clin Invest 2014;124:3656-3666.
    • (2014) J Clin Invest , vol.124 , pp. 3656-3666
    • Ko, J.H.1    Feigin, A.2    Mattis, P.J.3
  • 10
    • 19744378296 scopus 로고    scopus 로고
    • Levodopa and the progression of Parkinson's disease
    • Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
    • (2004) N Engl J Med , vol.351 , pp. 2498-2508
    • Fahn, S.1    Oakes, D.2    Shoulson, I.3
  • 11
    • 70349456475 scopus 로고    scopus 로고
    • A double-blind, delayed start trial of rasagiline in Parkinson's disease
    • Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-1278.
    • (2009) N Engl J Med , vol.361 , pp. 1268-1278
    • Olanow, C.W.1    Rascol, O.2    Hauser, R.3
  • 12
    • 0036906924 scopus 로고    scopus 로고
    • Design and analysis of two-period studies of potentially disease-modifying treatments
    • McDermott MP, Hall WJ, Oakes D, Eberly S. Design and analysis of two-period studies of potentially disease-modifying treatments. Control Clin Trials 2002;23:635-649
    • (2002) Control Clin Trials , vol.23 , pp. 635-649
    • McDermott, M.P.1    Hall, W.J.2    Oakes, D.3    Eberly, S.4
  • 13
    • 84919461672 scopus 로고    scopus 로고
    • Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa
    • Biaggioni J, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, on behalf of Droxidopa 302 Investigators. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension 2015;65(1):101-107.
    • (2015) Hypertension , vol.65 , Issue.1 , pp. 101-107
    • Biaggioni, J.1    Freeman, R.2    Mathias, C.J.3    Low, P.4    Hewitt, L.A.5    Kaufmann, H.6
  • 14
    • 84952037843 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
    • Tandon, Cucchiaro J, Phillips D, et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. J Psychopharmacol 2016;30(1):69-77.
    • (2016) J Psychopharmacol , vol.30 , Issue.1 , pp. 69-77
    • Tandon1    Cucchiaro, J.2    Phillips, D.3
  • 15
    • 84951325695 scopus 로고    scopus 로고
    • Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: a placebo-controlled, randomized withdrawal study
    • Findling RL, Chang K, Robb A, et al. Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: a placebo-controlled, randomized withdrawal study. J Am Acad Child Adolesc Psychiatry 2015;54:1020-1031.
    • (2015) J Am Acad Child Adolesc Psychiatry , vol.54 , pp. 1020-1031
    • Findling, R.L.1    Chang, K.2    Robb, A.3
  • 16
    • 0027530638 scopus 로고
    • Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
    • Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;32:176-183.
    • (1993) N Engl J Med , vol.32 , pp. 176-183
  • 17
    • 35148882113 scopus 로고    scopus 로고
    • Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
    • Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007;69:1480-1490.
    • (2007) Neurology , vol.69 , pp. 1480-1490
  • 18
    • 0025232430 scopus 로고
    • Parkinson's disease
    • Marsden CD. Parkinson's disease. Lancet 1990;335:948-952.
    • (1990) Lancet , vol.335 , pp. 948-952
    • Marsden, C.D.1
  • 19
    • 4844226577 scopus 로고    scopus 로고
    • Parkinsonian signs and substantia nigra neuron density in decendents elders without PD
    • Ross GW, Petrovitch H, Abbott RD, et al. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol 2004;56:532-539.
    • (2004) Ann Neurol , vol.56 , pp. 532-539
    • Ross, G.W.1    Petrovitch, H.2    Abbott, R.D.3
  • 20
    • 61949280270 scopus 로고    scopus 로고
    • Disease-modification” trials in Parkinson disease: target populations, endpoints and study design
    • Rascol O, “Disease-modification” trials in Parkinson disease: target populations, endpoints and study design. Neurology 2009;72(7 Suppl):S51-S58.
    • (2009) Neurology , vol.72 , Issue.7 , pp. S51-S58
    • Rascol, O.1
  • 21
    • 84932106482 scopus 로고    scopus 로고
    • Rational drug discovery design approaches for treating Parkinson's disease
    • Van der Schyf CJ., Rational drug discovery design approaches for treating Parkinson's disease, Expert Opin Drug Discov 2015;10(7):713-741.
    • (2015) Expert Opin Drug Discov , vol.10 , Issue.7 , pp. 713-741
    • Van der Schyf, C.J.1
  • 22
    • 84994744856 scopus 로고    scopus 로고
    • Challenges in detecting disease modification in Parkinson's disease clinical trials
    • Athauda D, Foltynie T. Challenges in detecting disease modification in Parkinson's disease clinical trials. Parkinsonism Relat Disord 2016;32:1-11.
    • (2016) Parkinsonism Relat Disord , vol.32 , pp. 1-11
    • Athauda, D.1    Foltynie, T.2
  • 23
    • 61449173973 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design
    • Olanow CW., Hauser RA., Jankovic J., et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design. Mov Disord 2008;23:2194-2201.
    • (2008) Mov Disord , vol.23 , pp. 2194-2201
    • Olanow, C.W.1    Hauser, R.A.2    Jankovic, J.3
  • 24
    • 84969915674 scopus 로고    scopus 로고
    • Magnetic resonance imaging as a potential biomarker for Parkinson's disease
    • Tuite P. Magnetic resonance imaging as a potential biomarker for Parkinson's disease. Transl Res 2016:175:4-16.
    • (2016) Transl Res , vol.175 , pp. 4-16
    • Tuite, P.1
  • 25
    • 84962860757 scopus 로고    scopus 로고
    • Magnetic resonance imaging features of the nigrostriatal system: biomarkers of Parkinson's disease stages?
    • Hopes L, Grolez G, Moreau C, et al. Magnetic resonance imaging features of the nigrostriatal system: biomarkers of Parkinson's disease stages? PLoS One 2016;11:e0147947.
    • (2016) PLoS One , vol.11
    • Hopes, L.1    Grolez, G.2    Moreau, C.3
  • 26
    • 84897930725 scopus 로고    scopus 로고
    • Targeting chelatable iron as a therapeutic modality in Parkinson's disease
    • Devos D, Moreau C, Devedjian JC, et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 2014;10;21(2):195-210.
    • (2014) Antioxid Redox Signal , vol.10 , Issue.2 , pp. 195-210
    • Devos, D.1    Moreau, C.2    Devedjian, J.C.3
  • 27
    • 84861325008 scopus 로고    scopus 로고
    • New developments of dopaminergic imaging in Parkinson's disease
    • Varrone A, Halldin C. New developments of dopaminergic imaging in Parkinson's disease. Q J Nucl Med Mol Imaging 2012;56:68-82.
    • (2012) Q J Nucl Med Mol Imaging , vol.56 , pp. 68-82
    • Varrone, A.1    Halldin, C.2
  • 28
    • 73049095463 scopus 로고    scopus 로고
    • Neuroprotection and imaging studies in Parkinson's disease
    • Pavese N, Kiferle L, Piccini P. Neuroprotection and imaging studies in Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl 4):S33-S37.
    • (2009) Parkinsonism Relat Disord , vol.15 , pp. S33-S37
    • Pavese, N.1    Kiferle, L.2    Piccini, P.3
  • 29
    • 84904126994 scopus 로고    scopus 로고
    • Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease
    • References for the Supplementary Material
    • Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J Parkinsons Dis 2014;4(3):337-344. References for the Supplementary Material
    • (2014) J Parkinsons Dis , vol.4 , Issue.3 , pp. 337-344
    • Aviles-Olmos, I.1    Dickson, J.2    Kefalopoulou, Z.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.